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Commentary
Recombinant peptides for gastrointestinal ulceration:
still early days
On page 204, Hull and colleagues examine the benefit of
using basic fibroblast growth factor to decrease aspirin
induced gastric and duodenal injury. Administration of
recombinantly produced, acid stable basic fibroblast
growth factor (bFGF, CS-23) decreased the amount of
duodenal, but not gastric, injury (erosions) induced by co-
administration of aspirin. In the second component of the
study, they gave indomethacin to the same subjects after
cessation of treatment with bFGF. Subjects who had
received bFGF in the first part of the study were found to
have a reduced susceptibility to indomethacin induced
relapse of artificially induced mini-ulcers. This suggests
that the mucosa was somehow 'stronger' in subjects who
had been treated with bFGF when compared with those
who had received placebo. This paper therefore highlights
two areas of interest; (1) the use of recombinant peptides
for the treatment of gastrointestinal disease and (2) the
concept of 'quality' of ulcer healing.
The most widely prescribed bioactive peptide used in
clinical practice is insulin and has been of undoubted
benefit to many thousands of patients. Peptides purified
from biological material (for example, porcine pancreas)
have usually been the initial source of peptides for clinical
usage. The risks of contamination with infectious agents
(as seen in patients treated with growth hormone devel-
oping Creutzfeldt-Jakob disease) and the development of
antibodies to the administered peptide, however, have
encouraged the development of recombinant peptide
technology.
The most widely prescribed recombinant peptide used
by gastroenterologists is probably interferon a for the
treatment of infective liver disease. Treatment results in a
long term 'cure' in only about 25% of patients with
hepatitis C and this must be borne in mind when one
considers the cost of a treatment course on a 'per patient'
basis (about £2000 per patient). The economic impli-
cations of using this drug are particularly relevant to less
well developed countries with high prevalence rates of
hepatitis C.
One of the most extensively studied peptides for the
treatment of gastrointestinal damage is epidermal growth
factor (EGF). EGF is a potent mitogenic factor normally
secreted into the intestinal lumen by the human salivary
glands and Brunners glands of the duodenum. It was
suggested many years ago that EGF may be a useful
treatment for gastrointestinal ulceration. Despite hundreds
of papers showing mitogenic activity and healing responses
in various animals models, it has failed to find a place in
clinical practice.
One of the major areas of concern of using peptides such
as EGF in the clinical setting is the worry that systemic
administration of growth factors may act to promote
tumour growth elsewhere in the body. It is partly for this
reason that there is increasing interest in the potential value
of trefoil peptides to treat human gastrointestinal disease,
as they seem to stimulate repair without increasing
proliferation. 1
Oral, as opposed to systemic, administration of growth
factors provides one possible approach to this problem.
However, for EGF and the trefoil peptides, the oral doses
required to treat gastrointestinal damage may be up to a
thousand times greater than when the peptide is given
systematically, making oral therapy economically un-
realistic.
One possible explanation for this is that the peptides
(like any other ingested food product) come into contact
with luminal proteases and may be digested into inactive
forms.2 In the paper by Hull, a recombinant modified form
of bFGF has been used to decrease the susceptibility to
acid and pepsin degradation. Stabilising against digestion
in the small intestine will probably be more difficult
because of the many different proteolytic enzymes pro-
duced by the pancreas. The peptide may have to be co-
administered with non-specific serine protease inhibitors
or in a site specific release formulation to overcome these
problems.
Most studies examining the potential value of recom-
binant growth factors to treat gastrointestinal disease have
examined their effects on gastric models of injury. Their
clinical value in peptic ulcer disease is, however, likely to
be small because of the high rate of success of ulcer healing
using acid suppressants and Helicobacter pylon' eradication
regimens. It is also relevant that the third group studied
by Hull and coworkers were treated with cimetidine, an
extremely cheap drug.
This group showed a similar protective effect against
aspirin induced duodenal injury and, like the bFGF treated
subjects, resulted in a reduced susceptibility to subsequent
indomethacin induced injury compared with placebo
treated subjects. Although many peptides have been shown
to decrease injury when given before the ulcerogen, there
is much less evidence that these peptides have a major
effect on the rate of healing when administered after the
damaging agent. These studies would obviously be of more
relevance to the clinical setting.
Two human studies that have shown a beneficial effect
of oral peptide therapy involved the use of basic fibroblast
growth factor therapy to treat patients with NSAID
associated gastric ulcers3 and using oral EGF to treat
patients with duodenal ulcer, where the healing efficacy
was similar to that ofusing cimetidine.4 Other peptides that
are presently under investigation include insulin-like
growth factor 1i and keratinocyte growth factor.6
Instead of administering exogenous peptide healing
factors, an alternative approach is to inhibit endogenous
peptide factors which may be exacerbating the injury.
Baert et al, for example, have recently shown that admin-
istration of a tumour necrosis factor ot neutralising anti-
body to patients with Crohn's disease considerably reduces
inflammatory activity.7 Tumour necrosis factor (x is
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thought to be an important mediator of the inflammatory
process.
The concept that ulcers may heal with different 'quality'
(that is, differences in the amount of residual submucosal
abnormalities seen on histological examination) is com-
paratively new and will probably be an important area of
further research.8 Patients who have taken NSAIDs have
impaired ulcer healing with a tendency to recurrence. The
mechanisms by which this occurs are unclear, although
areas of previous ulceration usually contain scar tissue and
disrupted histology despite appearing endoscopically
normal. Administration of peptides that stimulate repair,
such as bFGF which promotes angiogenesis, may result in
the scarred area having an improved vascular supply,
increasing its resilience to further injury.
In summary, recombinant peptides are (comparatively)
cheap and easy to produce and have the potential to treat
gastrointestinal damage in clinical diseases where treat-
ment is presently suboptimal. Problems to be overcome
include decreasing their susceptibility to luminal digestion
and finding peptides that are capable of stimulating healing
when given after ulceration has occurred. In the next few
years we will probably see an increasing number of peptide
therapy studies being extended from the laboratory
environment into the clinics.
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